Cargando…

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

INTRODUCTION: The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sassen, Andrea, Rochon, Justine, Wild, Peter, Hartmann, Arndt, Hofstaedter, Ferdinand, Schwarz, Stephan, Brockhoff, Gero
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374953/
https://www.ncbi.nlm.nih.gov/pubmed/18182100
http://dx.doi.org/10.1186/bcr1843
_version_ 1782154544738729984
author Sassen, Andrea
Rochon, Justine
Wild, Peter
Hartmann, Arndt
Hofstaedter, Ferdinand
Schwarz, Stephan
Brockhoff, Gero
author_facet Sassen, Andrea
Rochon, Justine
Wild, Peter
Hartmann, Arndt
Hofstaedter, Ferdinand
Schwarz, Stephan
Brockhoff, Gero
author_sort Sassen, Andrea
collection PubMed
description INTRODUCTION: The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and cross-activation. The most famous family member is HER2, which is a target in Herceptin™ therapy in metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of gene amplification and resulting protein overexpression. The HER2-related HER receptors have been shown to interact directly with HER2 receptors and thereby mutually affect their activity and subsequent malignant growth potential. However, the clinical outcome with regard to total HER receptor state remains largely unknown. METHODS: We investigated HER1–HER4, at both the DNA and the protein level, using fluorescence in situ hybridisation (FISH) probes targeted to all four receptor loci and also immunohistochemistry in tissue microarrays derived from 278 breast cancer patients. RESULTS: We retrospectively found HER3 gene amplification with a univariate negative impact on disease-free survival (hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p = 0.031), whereas HER4 amplification showed a positive trend in overall and disease-free survival. Protein expression revealed no additional information. CONCLUSION: Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information. The continuation of explorative and prospective studies on all HER receptors will be required for an evaluation of their potential use for specific therapeutic targeting with respect to individualised therapy.
format Text
id pubmed-2374953
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23749532008-05-10 Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients Sassen, Andrea Rochon, Justine Wild, Peter Hartmann, Arndt Hofstaedter, Ferdinand Schwarz, Stephan Brockhoff, Gero Breast Cancer Res Research Article INTRODUCTION: The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and cross-activation. The most famous family member is HER2, which is a target in Herceptin™ therapy in metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of gene amplification and resulting protein overexpression. The HER2-related HER receptors have been shown to interact directly with HER2 receptors and thereby mutually affect their activity and subsequent malignant growth potential. However, the clinical outcome with regard to total HER receptor state remains largely unknown. METHODS: We investigated HER1–HER4, at both the DNA and the protein level, using fluorescence in situ hybridisation (FISH) probes targeted to all four receptor loci and also immunohistochemistry in tissue microarrays derived from 278 breast cancer patients. RESULTS: We retrospectively found HER3 gene amplification with a univariate negative impact on disease-free survival (hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p = 0.031), whereas HER4 amplification showed a positive trend in overall and disease-free survival. Protein expression revealed no additional information. CONCLUSION: Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information. The continuation of explorative and prospective studies on all HER receptors will be required for an evaluation of their potential use for specific therapeutic targeting with respect to individualised therapy. BioMed Central 2008 2008-01-08 /pmc/articles/PMC2374953/ /pubmed/18182100 http://dx.doi.org/10.1186/bcr1843 Text en Copyright © 2008 Sassen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sassen, Andrea
Rochon, Justine
Wild, Peter
Hartmann, Arndt
Hofstaedter, Ferdinand
Schwarz, Stephan
Brockhoff, Gero
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
title Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
title_full Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
title_fullStr Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
title_full_unstemmed Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
title_short Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
title_sort cytogenetic analysis of her1/egfr, her2, her3 and her4 in 278 breast cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374953/
https://www.ncbi.nlm.nih.gov/pubmed/18182100
http://dx.doi.org/10.1186/bcr1843
work_keys_str_mv AT sassenandrea cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients
AT rochonjustine cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients
AT wildpeter cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients
AT hartmannarndt cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients
AT hofstaedterferdinand cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients
AT schwarzstephan cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients
AT brockhoffgero cytogeneticanalysisofher1egfrher2her3andher4in278breastcancerpatients